BTKi Resistance Mutations – Re-test Your Knowledge
October 4, 2024
BTKi Resistance Mutations – Post-test
BTKi Resistance Mutations – Post-test
Learn about resistance mutations in chronic lymphocytic leukemia (CLL), specifically in BTK inhibitor drugs, to understand why treatment may stop working.
BTKi Resistance Mutations Learning Activity Pre-test – CLL Society
Resistance mutations in BTK and PLCG2 are common in patients with CLL who progress on acalabrutinib, a BTK inhibitor treatment that is taken continuously.
A newly published paper in Clinical Cancer Research found that when patients successfully treated with fixed-duration ibrutinib-venetoclax developed progressive disease, they had no acquired resistance mutations in BTK, BCL2, or PLCG2.
Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).
Join Dr. Koffman as he and Dr. Adrian Wiestner discuss A New Oral BTK Protein Degrader: A novel drug designed to overcome resistance to BTK Inhibitors.
Bruton tyrosine kinase (BTK) degraders are a new therapeutic area that might be able to overcome mutations that cause resistance to BTK inhibitors.
In this study published in the New England Journal of Medicine in February 2022, a large group of researchers performed genetic testing in patients before treatment and in patients that relapsed or failed treatment with the noncovalent BTKi, Pirtobrutinib. These tests allowed the researchers to discover many other genetic mutations in CLL / SLL cells.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911